AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25412051 — intervention group
Group type: EXPERIMENTAL
Intervention: Single ultrasound-guided regional nerve block of the lateral femoral cutaneous nerve (LFCN)
Number of subjects: 19
Study 25412051 — intervention group
Group type: EXPERIMENTAL
Intervention: Fascia iliaca compartment block with catheter placement and continuous infusion
Number of subjects: 19
Study 25412051 — intervention group
Group type: COMPARATOR
Intervention: Local anesthetic infiltration
Number of subjects: 19
Study 25412051 — intervention group
Group type: EXPERIMENTAL
Intervention: All regional anesthesia groups (LFCN block and compartment block)
Number of subjects: 19
Study 24694531 — intervention group
Group type: EXPERIMENTAL
Intervention: Evolocumab 140 mg Q2W
Number of subjects: 307
Study 24694531 — intervention group
Group type: EXPERIMENTAL
Intervention: Evolocumab 420 mg QM
Number of subjects: 307
Study 24694531 — intervention group
Group type: COMPARATOR
Intervention: Ezetimibe 10 mg
Number of subjects: 307
Study 24694531 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 307
Study 23713082 — intervention group
Group type: EXPERIMENTAL
Intervention: BAY 94‐8862 (2.5, 5, or 10 mg once daily)
Number of subjects: 392
Study 23713082 — intervention group
Group type: EXPERIMENTAL
Intervention: BAY 94‐8862 (5-10 mg/day)
Number of subjects: 392
Study 23713082 — intervention group
Group type: COMPARATOR
Intervention: Spironolactone (25 or 50 mg/day)
Number of subjects: 392
Study 20138976 — intervention group
Group type: EXPERIMENTAL
Intervention: Retention interval (RI) of 1.5, 3, 24 or 48 hours
Number of subjects: 0
Study 20138976 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate test after training
Number of subjects: 0
Study 19132268 — intervention group
Group type: EXPERIMENTAL
Intervention: Agaricus sylvaticus fungus (30 mg/kg/day)
Number of subjects: 56
Study 19132268 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 16629794 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus 0.1% ointment
Number of subjects: 8
Study 16629794 — intervention group
Group type: COMPARATOR
Intervention: Triamcinolone acetonide 0.1% ointment
Number of subjects: 8
Study 16629794 — intervention group
Group type: COMPARATOR
Intervention: Cetomacrogol ointment (placebo)
Number of subjects: 8
Study 14636982 — intervention group
Group type: COMPARATOR
Intervention: Artesunate alone (50 mg rectal capsules, 40 mg/kg total dose over 6 days)
Number of subjects: 150
Study 14636982 — intervention group
Group type: EXPERIMENTAL
Intervention: Artesunate (50 mg rectal capsules, 30 mg/kg total dose for 3 days) + Mefloquine (20 mg/kg total dose on day 1)
Number of subjects: 150
Study 14636982 — intervention group
Group type: EXPERIMENTAL
Intervention: Artesunate (50 mg rectal capsules, 30 mg/kg total dose for 3 days) + Mefloquine (15-17 mg/kg total dose on days 1 and 3)
Number of subjects: 150
Study 10933177 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral blood stem cells (PBSC)
Number of subjects: 108
Study 10933177 — intervention group
Group type: COMPARATOR
Intervention: Bone marrow
Number of subjects: 108
Study 10933177 — intervention group
Group type: EXPERIMENTAL
Intervention: CD34-selected PBSC
Number of subjects: 108
Study 10933177 — intervention group
Group type: EXPERIMENTAL
Intervention: PBSC
Number of subjects: 108
Study 8672384 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine and adrenaline 1/200,000 (B+E) 8 ml before incision and saline 8 ml after incision
Number of subjects: 45
Study 8672384 — intervention group
Group type: EXPERIMENTAL
Intervention: Saline 8 ml before incision and B+E 8 ml after incision
Number of subjects: 45
Study 8672384 — intervention group
Group type: COMPARATOR
Intervention: Saline 8 ml before and after incision
Number of subjects: 45
Study 8672384 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 45
Study 2261385 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole breast and regional lymph node areas radiotherapy (WF group)
Number of subjects: 708
Study 2261385 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy to the affected quadrant only (LF group)
Number of subjects: 708
Study 2261385 — intervention group
Group type: EXPERIMENTAL
Intervention: Tumours histologically 1 cm or less in diameter
Number of subjects: 708
Study 2261385 — intervention group
Group type: COMPARATOR
Intervention: Tumours measuring 2 cm or more in diameter
Number of subjects: 708
Study 78446 — intervention group
Group type: EXPERIMENTAL
Intervention: Venom immunotherapy
Number of subjects: 20
Study 78446 — intervention group
Group type: COMPARATOR
Intervention: Whole-body extract
Number of subjects: 20
Study 78446 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 30689969 — intervention group
Group type: EXPERIMENTAL
Intervention: Trial group with additional intraoperative splint for verification of implants' angulation
Number of subjects: 8
Study 30689969 — intervention group
Group type: COMPARATOR
Intervention: Control group with preplanned fibular reconstructions without additional splint
Number of subjects: 8
Study 27690747 — intervention group
Group type: EXPERIMENTAL
Intervention: Er:YAG laser treatment
Number of subjects: 46
Study 25325193 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based cultural competency training
Number of subjects: 180
Study 25325193 — intervention group
Group type: COMPARATOR
Intervention: Lecture-based cultural competency training
Number of subjects: 180
Study 23192844 — intervention group
Group type: EXPERIMENTAL
Intervention: Mn‐supplemented diet
Number of subjects: 1
Study 23192844 — intervention group
Group type: COMPARATOR
Intervention: Commercial diet
Number of subjects: 1
Study 21812570 — intervention group
Group type: EXPERIMENTAL
Intervention: Theta-band activity over medial frontal scalp sites after negative feedback
Number of subjects: 0
Study 21812570 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-band activity after positive feedback
Number of subjects: 0
Study 21812570 — intervention group
Group type: EXPERIMENTAL
Intervention: Theta-band power
Number of subjects: 0
Study 21812570 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-band power
Number of subjects: 0
Study 21812570 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative feedback
Number of subjects: 0
Study 19815402 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol maintenance and reliever therapy
Number of subjects: 14346
Study 15804591 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture analgesia with general anaesthesia
Number of subjects: 120
Study 15804591 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture analgesia in addition to traditional postoperative analgesia
Number of subjects: 120
Study 12858407 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-HCV treatment in HIV-coinfected patients
Number of subjects: 52
Study 9796763 — intervention group
Group type: EXPERIMENTAL
Intervention: Colchicine treatment for 8 weeks
Number of subjects: 12
Study 9796763 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment for 8 weeks
Number of subjects: 12
Study 7658535 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypospadias patients
Number of subjects: 73
Study 7658535 — intervention group
Group type: COMPARATOR
Intervention: Comparison subjects
Number of subjects: 73
Study 2756879 — intervention group
Group type: EXPERIMENTAL
Intervention: pindolol
Number of subjects: 12
Study 2756879 — intervention group
Group type: EXPERIMENTAL
Intervention: propranolol
Number of subjects: 12
Study 2756879 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 12
Study 79760 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolfenamic acid (T.A.)
Number of subjects: 160
Study 79760 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160
Study 31924551 — intervention group
Group type: EXPERIMENTAL
Intervention: Xpert MTB/RIF Ultra
Number of subjects: 205
Study 31924551 — intervention group
Group type: COMPARATOR
Intervention: Xpert MTB/RIF
Number of subjects: 205
Study 30431575 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuromuscular electrical stimulation (NMES) applied to quadriceps and gastrocnemius for 60 minutes, for up to 10 sessions.
Number of subjects: 59
Study 30431575 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care without NMES)
Number of subjects: 59
Study 30431575 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuromuscular electrical stimulation (NMES)
Number of subjects: 59
Study 27710263 — intervention group
Group type: EXPERIMENTAL
Intervention: Peginterferon lambda‐1a (Lambda) with ribavirin (RBV)
Number of subjects: 0
Study 27710263 — intervention group
Group type: COMPARATOR
Intervention: Peginterferon alfa‐2a (Alfa) with ribavirin (RBV)
Number of subjects: 0
Study 25789311 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacrocolpopexy during cystectomy
Number of subjects: 24
Study 25789311 — intervention group
Group type: COMPARATOR
Intervention: Control group (no sacrocolpopexy)
Number of subjects: 24
Study 23595582 — intervention group
Group type: EXPERIMENTAL
Intervention: Medroxyprogesterone acetate (MPA) for 21 days from day 5 of menses
Number of subjects: 90
Study 23595582 — intervention group
Group type: COMPARATOR
Intervention: Tranexamic acid (TA) for 5 days from day 1 of menses
Number of subjects: 90
Study 19863619 — intervention group
Group type: EXPERIMENTAL
Intervention: FPV 1400 mg bid with TDF 300 mg qd
Number of subjects: 36
Study 19863619 — intervention group
Group type: EXPERIMENTAL
Intervention: FPV/RTV 700/100 mg bid with TDF 300 mg qd
Number of subjects: 36
Study 19863619 — intervention group
Group type: COMPARATOR
Intervention: FPV 1400 mg bid without TDF
Number of subjects: 36
Study 19863619 — intervention group
Group type: COMPARATOR
Intervention: FPV/RTV 700/100 mg bid without TDF
Number of subjects: 36
Study 18661061 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid Palatal Expansion (RPE)
Number of subjects: 19
Study 18661061 — intervention group
Group type: COMPARATOR
Intervention: Damon appliance
Number of subjects: 19
Study 15679715 — intervention group
Group type: EXPERIMENTAL
Intervention: Omalizumab
Number of subjects: 419
Study 15679715 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 419
Study 12893904 — intervention group
Group type: EXPERIMENTAL
Intervention: Undiluted direct injection of ferumoxides (0.56 mg of iron per kg of body weight, administered during 2 minutes at 2 mL/min)
Number of subjects: 233
Study 12893904 — intervention group
Group type: COMPARATOR
Intervention: Diluted slow infusion of ferumoxides (administered during 30 minutes)
Number of subjects: 233
Study 12893904 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions (direct injection and slow infusion)
Number of subjects: 233
Study 10589310 — intervention group
Group type: EXPERIMENTAL
Intervention: teacher/self-preparation
Number of subjects: 100
Study 10589310 — intervention group
Group type: EXPERIMENTAL
Intervention: teacher/workshop
Number of subjects: 100
Study 10589310 — intervention group
Group type: EXPERIMENTAL
Intervention: nurse/self-preparation
Number of subjects: 100
Study 10589310 — intervention group
Group type: EXPERIMENTAL
Intervention: nurse/workshop
Number of subjects: 100
Study 10589310 — intervention group
Group type: COMPARATOR
Intervention: control
Number of subjects: 100
Study 9005789 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofloxacin 400 mg intravenous followed by 400 mg oral once a day for at least 14 days
Number of subjects: 0
Study 9005789 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofloxacin 400 mg oral once a day
Number of subjects: 0
Study 9005789 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofloxacin (various regimens: 200 mg thrice a day, 200 mg twice a day, 400 mg once a day)
Number of subjects: 0
Study 1685055 — intervention group
Group type: EXPERIMENTAL
Intervention: Gamma-nail
Number of subjects: 100
Study 1685055 — intervention group
Group type: COMPARATOR
Intervention: DHS
Number of subjects: 100
Study 6781586 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg/m2 (low dose)
Number of subjects: 72
Study 6781586 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg/m2 (medium dose)
Number of subjects: 72
Study 6781586 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 g/m2 (high dose)
Number of subjects: 72
Study 6781586 — intervention group
Group type: EXPERIMENTAL
Intervention: Cross-over to higher dose
Number of subjects: 72
Study 6781586 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose regimen
Number of subjects: 72
Study 6781586 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients who completed first four treatments
Number of subjects: 72
Study 31622456 — intervention group
Group type: EXPERIMENTAL
Intervention: Early ART initiation during TB treatment
Number of subjects: 642
Study 31622456 — intervention group
Group type: EXPERIMENTAL
Intervention: Late ART initiation during TB treatment
Number of subjects: 642
Study 31622456 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential ART initiation after TB treatment completion
Number of subjects: 642
Study 31622456 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 642
Study 30682067 — intervention group
Group type: EXPERIMENTAL
Intervention: TAU plus the employment of Voices, an online self‐training program for prosodic rehabilitation
Number of subjects: 50
Study 30682067 — intervention group
Group type: COMPARATOR
Intervention: Treatment‐as‐usual (TAU)
Number of subjects: 50
Study 28548619 — intervention group
Group type: EXPERIMENTAL
Intervention: Moti-4 intervention
Number of subjects: 131
Study 28548619 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 131
Study 25268539 — intervention group
Group type: EXPERIMENTAL
Intervention: Playworks program (intervention group)
Number of subjects: 365
Study 25268539 — intervention group
Group type: COMPARATOR
Intervention: Single-day measurement (control group)
Number of subjects: 365
Study 23522530 — intervention group
Group type: EXPERIMENTAL
Intervention: Phentolamine administered at 30 minutes after IAN block
Number of subjects: 90
Study 23522530 — intervention group
Group type: EXPERIMENTAL
Intervention: Phentolamine administered at 60 minutes after IAN block
Number of subjects: 90
Study 23522530 — intervention group
Group type: COMPARATOR
Intervention: Sham injection at 30 minutes and phentolamine at 60 minutes
Number of subjects: 90
Study 23522530 — intervention group
Group type: COMPARATOR
Intervention: Phentolamine at 30 minutes and sham at 60 minutes
Number of subjects: 90
Study 22397236 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilates training group (PTG; N = 34)
Number of subjects: 58
Study 22397236 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG; N = 27)
Number of subjects: 58
Study 19267842 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical hyaluronic acid (HA) gel preparation (0.2%)
Number of subjects: 124
Study 19267842 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 124
Study 17539712 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycine powder air polishing (GPAP) performed in teeth instrumented 3 months earlier
Number of subjects: 60
Study 17539712 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycine powder air polishing (GPAP) performed in previously non‐instrumented teeth
Number of subjects: 60
Study 17539712 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 60
Study 14744178 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine (2.5 to 20 mg/day, most receiving 5 to 10 mg/day)
Number of subjects: 40
Study 14744178 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 40
Study 14744178 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 11099053 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 microg/ml hr-EGF
Number of subjects: 103
Study 11099053 — intervention group
Group type: COMPARATOR
Intervention: 10 microg/ml hr-EGF
Number of subjects: 103
Study 11099053 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 103
Study 9254399 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin
Number of subjects: 127
Study 9254399 — intervention group
Group type: EXPERIMENTAL
Intervention: Pivmecillinam
Number of subjects: 127
Study 8445427 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal methotrexate (IT MTX)
Number of subjects: 1388
Study 8445427 — intervention group
Group type: COMPARATOR
Intervention: Cranial radiation (CXRT)
Number of subjects: 1388
Study 8445427 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive systemic therapy with either IT MTX or CXRT
Number of subjects: 1388
Study 8445427 — intervention group
Group type: COMPARATOR
Intervention: Standard systemic therapy with CXRT
Number of subjects: 1388
Study 8445427 — intervention group
Group type: COMPARATOR
Intervention: Standard systemic therapy with IT MTX
Number of subjects: 1388
Study 8445427 — intervention group
Group type: EXPERIMENTAL
Intervention: CXRT in patients 10 years or older with intensive systemic therapy
Number of subjects: 1388
Study 8445427 — intervention group
Group type: EXPERIMENTAL
Intervention: IT MTX in patients 10 years or older with intensive systemic therapy
Number of subjects: 1388
Study 8445427 — intervention group
Group type: EXPERIMENTAL
Intervention: IT MTX in patients less than 10 years of age with intensive systemic therapy
Number of subjects: 1388
Study 8445427 — intervention group
Group type: EXPERIMENTAL
Intervention: CXRT in patients less than 10 years of age with intensive systemic therapy
Number of subjects: 1388
Study 3771022 — intervention group
Group type: EXPERIMENTAL
Intervention: Cordial substitution group (methadone-associated cordial)
Number of subjects: 40
Study 3771022 — intervention group
Group type: COMPARATOR
Intervention: Standard detoxification group
Number of subjects: 40
Study 29788996 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided web-based intervention with treatment as usual and immediate access to the web-based intervention
Number of subjects: 0
Study 29788996 — intervention group
Group type: COMPARATOR
Intervention: Waiting control condition with treatment as usual and delayed access to the web-based intervention
Number of subjects: 0
Study 27338551 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical lidocaine spray (group L)
Number of subjects: 322
Study 27338551 — intervention group
Group type: COMPARATOR
Intervention: Saline (group S)
Number of subjects: 322
Study 25548768 — intervention group
Group type: EXPERIMENTAL
Intervention: Vinpocetine and pyritinol
Number of subjects: 30
Study 22759255 — intervention group
Group type: EXPERIMENTAL
Intervention: SGP‐HA (≤1.5 mL/lip)
Number of subjects: 180
Study 22759255 — intervention group
Group type: EXPERIMENTAL
Intervention: SGP‐HA
Number of subjects: 180
Study 22759255 — intervention group
Group type: COMPARATOR
Intervention: no treatment
Number of subjects: 180
Study 20041473 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextromethorphan (DM) with quinidine pre-treatment
Number of subjects: 8
Study 20041473 — intervention group
Group type: COMPARATOR
Intervention: Dextromethorphan (DM) alone
Number of subjects: 8
Study 17922883 — intervention group
Group type: EXPERIMENTAL
Intervention: MDI + SP (metered dose inhaler plus spacer)
Number of subjects: 30
Study 17922883 — intervention group
Group type: COMPARATOR
Intervention: NEB (Sidestream nebulizer)
Number of subjects: 30
Study 17922883 — intervention group
Group type: EXPERIMENTAL
Intervention: MDI + SP
Number of subjects: 30
Study 15919182 — intervention group
Group type: EXPERIMENTAL
Intervention: N400 amplitude to non-exemplars
Number of subjects: 0
Study 15919182 — intervention group
Group type: EXPERIMENTAL
Intervention: N400 amplitude to high-typicality exemplars
Number of subjects: 0
Study 15919182 — intervention group
Group type: EXPERIMENTAL
Intervention: N400 amplitude to low-typicality exemplars
Number of subjects: 0
Study 15919182 — intervention group
Group type: EXPERIMENTAL
Intervention: N400 amplitude difference between non-exemplars and both low- and high-typicality exemplars
Number of subjects: 0
Study 15919182 — intervention group
Group type: EXPERIMENTAL
Intervention: N400 amplitude difference between low- and high-typicality exemplars
Number of subjects: 0
Study 15919182 — intervention group
Group type: EXPERIMENTAL
Intervention: N400 amplitude differences between non-exemplars and both types of exemplars
Number of subjects: 0
Study 12815491 — intervention group
Group type: EXPERIMENTAL
Intervention: Community volunteers
Number of subjects: 0
Study 12815491 — intervention group
Group type: COMPARATOR
Intervention: Village government personnel
Number of subjects: 0
Study 10448447 — intervention group
Group type: EXPERIMENTAL
Intervention: Volunteer befriending
Number of subjects: 0
Study 10448447 — intervention group
Group type: EXPERIMENTAL
Intervention: Fresh-start experiences
Number of subjects: 0
Study 10448447 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard attachment style
Number of subjects: 0
Study 10448447 — intervention group
Group type: EXPERIMENTAL
Intervention: New severe stressors and poor coping strategies
Number of subjects: 0
Study 7540445 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyethyl starch 200,000/0.62 6%
Number of subjects: 24
Study 7540445 — intervention group
Group type: COMPARATOR
Intervention: Human albumin 5%
Number of subjects: 24
Study 7540445 — intervention group
Group type: EXPERIMENTAL
Intervention: Isovolemic hemodilution
Number of subjects: 24
Study 2085986 — intervention group
Group type: EXPERIMENTAL
Intervention: Fosfomycin trometamol (3 g)
Number of subjects: 89
Study 2085986 — intervention group
Group type: COMPARATOR
Intervention: Norfloxacin (800 mg)
Number of subjects: 89
Study 2085986 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 89
Study 398184 — intervention group
Group type: EXPERIMENTAL
Intervention: Labetalol
Number of subjects: 0
Study 398184 — intervention group
Group type: COMPARATOR
Intervention: Pindolol
Number of subjects: 0
Study 31232920 — intervention group
Group type: EXPERIMENTAL
Intervention: CCR with PBM Therapy (CR-PBM)
Number of subjects: 90
Study 31232920 — intervention group
Group type: COMPARATOR
Intervention: CCR and placebo PBM Therapy (CR-PlaceboPBM)
Number of subjects: 90
Study 31232920 — intervention group
Group type: COMPARATOR
Intervention: Control, only cardiorespiratory rehabilitation (CCR)
Number of subjects: 90
Study 28715325 — intervention group
Group type: EXPERIMENTAL
Intervention: Inference-based framework for privacy-preserving similarity search in Hamming space; specific dosage and duration not applicable.
Number of subjects: 0
Study 26968623 — intervention group
Group type: EXPERIMENTAL
Intervention: Mometasone furoate (investigational drug)
Number of subjects: 0
Study 26968623 — intervention group
Group type: COMPARATOR
Intervention: Control drug (mometasone furoate)
Number of subjects: 0
Study 25050491 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine (2.5 mg/kg)
Number of subjects: 61